Stryker Corporation $SYK Stock Bought by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 767,516 shares of the medical technology company’s stock after purchasing an additional 26,311 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Stryker were worth $211,366,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Gables Capital Management Inc. acquired a new position in shares of Stryker during the 2nd quarter worth approximately $25,000. Kilter Group LLC acquired a new position in shares of Stryker during the second quarter worth $25,000. Cornerstone Financial Management LLC increased its stake in Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Highland Investment Advisors LLC acquired a new stake in shares of Stryker during the second quarter worth about $25,000. Finally, Compass Financial Management LLC acquired a new stake in Stryker during the 2nd quarter worth $27,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 over the last ninety days. Insiders own 4.60% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Wall Street Analyst Weigh In

SYK has been the subject of several recent analyst reports. Needham & Company LLC reduced their price objective on shares of Stryker from $418.00 to $359.00 and set a “buy” rating for the company in a research note on Friday. TD Cowen cut their target price on Stryker from $298.00 to $290.00 and set a “hold” rating on the stock in a research report on Friday. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. UBS Group started coverage on Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price for the company. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $309.00 target price on shares of Stryker in a research note on Friday. Sixteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $355.84.

Stryker Stock Down 0.1%

SYK opened at $291.56 on Monday. The business has a 50-day moving average of $292.83 and a 200-day moving average of $324.51. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The company has a market capitalization of $111.83 billion, a PE ratio of 31.05, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter last year, the business earned $3.19 EPS. Equities research analysts forecast that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker’s payout ratio is currently 37.49%.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.